New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:35 EDTEDAPEDAP submits FDA PMA application for Ablatherm-HIFU
EDAP TMS announced the submission of its Pre-Market Approval, or PMA, application to the FDA on January 31 for the company's Ablatherm-HIFU. or High Intensity Focused Ultrasound, for treatment of low risk, localized prostate cancer. EDAP's PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two-year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the company's extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer.
News For EDAP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for EDAP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use